Scotiabank lowered the firm’s price target on Geron (GERN) to $4 from $6 and keeps an Outperform rating on the shares. While the company’s Q4 results were in-line with expectations, the shares are weaker following management comments that the Rytelo launch in lower-risk myelodysplastic syndromes has slowed, the analyst tells investors. The firm believes the slowdown is a cause for concern at this stage of the launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN:
- Geron price target lowered to $4 from $9 at Barclays
- Geron Corporation Reports Strong 2024 Financial Results
- Geron downgraded to Neutral from Buy at B. Riley
- Geron Inc.: Strategic Market Position and Rytelo’s Potential Justify Buy Rating
- Geron’s Strategic Focus on Regional Engagement and Early Line Uptake to Drive Growth